Last Price
12.50
Today's Change
0.00 (0.00%)
Day's Change
12.44 - 12.65
Trading Volume
70,791
Market Cap
888 Million
Shares Outstanding
71 Million
Avg Volume
734,593
Avg Price (50 Days)
11.10
Avg Price (200 Days)
10.20
PE Ratio
-8.33
EPS
-1.50
Earnings Announcement
05-Nov-2024
Previous Close
12.50
Open
12.51
Day's Range
12.44 - 12.65
Year Range
6.015 - 13.27
Trading Volume
71,151
1 Day Change
0.00%
5 Day Change
-4.14%
1 Month Change
9.75%
3 Month Change
49.52%
6 Month Change
20.19%
Ytd Change
20.42%
1 Year Change
95.92%
3 Year Change
-57.78%
5 Year Change
-53.70%
10 Year Change
-3.85%
Max Change
-3.85%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.